The Pancreatic Cancer Europe (PCE) is a European multi-stakeholder platform, which aims at bringing together experts from all over Europe including academics, physicians, politicians, patient groups, journalists and industry with a common interest and willingness to improve care for patients with pancreatic cancer.
PCE launches a call for a short-term scientific stay award (S3A) to train one or more Early Career Investigators (ECI) on pancreatic cancer research.
The S3A pretends to consolidate existing networks of pancreatic cancer research, as well as to set up new partnerships and collaborations between high-level pancreatic cancer research institutions. It should also allow ECI to go to an institution or laboratory in another European country to learn a new technique or to take measurements using instruments and/or methods not available in their own institution or laboratory.
For the period of the S3A, PCE should be not considered as the employer and the grantee must make his or her own arrangements for all health, social, personal security and pension matters.
An S3A can ONLY be planned from a home institution in an EU country to a host institution in another EU country.
Candidates can apply for grant support for a research stay from 1 to 3 months duration. The stay should take place and end before 30 November 2022.
The applicant is responsible for obtaining the agreement of the host institution, before submitting his or her application.
The award is not intended to cover expenses for participation in scientific conferences or meetings; it is crucial that the S3A aims to boost the research training on pancreatic cancer.
At the end of the S3A, the ECI should deliver a report containing the achievements of the supported project, to be published within the relevant PCE communication channels.
Interested candidates should send the application form with the requested attachments, in English, to email@example.com by Tuesday, 31 May 2022.
The editable application form is available at the following link:
All applications received will be treated with the utmost confidentiality.
Applications will be evaluated against the following criteria:
- Candidates could be:
- ECIs with a completed PhD no more than 5 years ago
- PhD students researching Pancreatic Cancer.
- The applicant should be engaged in a program of research as a postgraduate student or postdoctoral fellow or be employed in an institution in an EU country.
- The applicant should prove some research experience focusing on pancreatic cancer. His or her educational background, degrees and diplomas, professional experience, research work and publications will be valuable.
- The host institution shall be actively participating in pancreatic cancer research and should be internationally recognized for this activity. The agreement of the host institution will be a request to submit the application.
The evaluation process will follow soon after the deadline expiration and will be carried out by an independent committee appointed by the PCE Board of Directors. The results will be communicated by Monday, 20 June 2022.
The grant is a fixed amount based on the applicant’s budget request and the evaluation of the application, and will not exceed EUR 5.000.
The following expenses are considered eligible costs:
- Travel, with the cheapest fares;
- Daily allowance, as indicated in Annex 1 to this call;
- Visa expenses, if needed,
- Other direct costs, if needed and fully justified in the application.
The beneficiary will be asked to provide proof of the travel and visa expenses.
An advanced payment of 90% of the total award budget will be paid upon signature of the agreement, while the balance payment will be done upon receiving the activities and financial report.
For further information, please contact firstname.lastname@example.org; additional information about PCE available at www.pancreaticcancereurope.eu